Portfolio Co Investors 2026 for Eli Lilly and Company: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.
Eli Lilly and Company accounts for 41 tracked companies with verified cap-table data, 41 of which disclose round sizes totalling $4.7B. The median disclosed raise is $90M, and the largest is Delfi Diagnostics at $400M, ahead of Sigilon Therapeutics ($363M) and Flare Therapeutics ($287M).
The names that recur most often on these co-invested cap tables are Eli Lilly and Company (41 companies), Pfizer Ventures (6 companies), Invus (6 companies), Alexandria Venture Investments (6 companies), RA Capital Management (4 companies), Sofinnova Partners (4 companies). By latest disclosed round, the market skews Series A (18), Series B (14), Series C (4), Growth (1).
Companies tracked: 41
Disclosed funding total: $4.7B across 41 companies
Median disclosed raise: $90M
Largest raise: Delfi Diagnostics — $400M
Stage mix: Series A 18 · Series B 14 · Series C 4 · Growth 1
